THE SCIENCE

We measure first. Then we recommend.

Every recommendation Ody makes traces back to a number on a lab report. The panel below is the one we run on every member, regardless of protocol.

The panel we run.

Hormones, the metabolic panel, lipids, and inflammatory markers — collected once at baseline and again at the three-month follow-up. The panel is broader than what most primary-care visits include and is designed to surface drift before it becomes diagnosis.

Hormone values are read against age-stratified reference ranges, not the population-wide ranges that flag a 55-year-old as “normal” at the same threshold as a 25-year-old. The metabolic panel is screened for early insulin resistance long before fasting glucose moves out of range.

Markers flagged in gold are below or above your individual reference range. The system never colors a value red — gold is the only signal of attention. Out-of-range values are surfaced to the prescribing physician before any protocol is recommended.

WHAT WE MEASURE

Baseline Panel

Total Testosterone412 ng/dL
300REF RANGE1000
Free Testosterone6.8 pg/mL
8.7BELOW RANGE25.1
SHBG38 nmol/L
16.5REF RANGE55.9
Estradiol (E2)22 pg/mL
7.6REF RANGE42.6
Fasting Glucose92 mg/dL
70REF RANGE99
HbA1c5.4 %
4REF RANGE5.6
Fasting Insulin11.2 µIU/mL
2.6REF RANGE24.9
LDL Cholesterol142 mg/dL
0ABOVE RANGE130
HDL Cholesterol48 mg/dL
40REF RANGE80
Triglycerides118 mg/dL
0REF RANGE150
hs-CRP2.4 mg/L
0REF RANGE3
Homocysteine9.1 µmol/L
4REF RANGE15
Vitamin D, 25-OH26 ng/mL
30BELOW RANGE100

What the research says.

RESEARCH · 01

Hormone optimization and longevity.

Endogenous testosterone in the lower quartile correlates with all-cause mortality in adult men, independent of obesity and cardiometabolic disease. Restoration to mid-range — not supraphysiologic — is the clinically supported target.

→ See citations

RESEARCH · 02

NAD+ and cellular aging.

NAD+ levels decline measurably with age and correlate with mitochondrial output, sirtuin activity, and DNA repair capacity. Precursor supplementation has shown a measurable rise in tissue NAD+ in human pharmacokinetic studies.

→ See citations

RESEARCH · 03

Peptide therapy safety profile.

Growth hormone secretagogues used at endocrine-pulsatile doses produce a measurable rise in IGF-1 within physiologic range. Long-term safety registries to date have not flagged the risk signals associated with exogenous GH.

→ See citations

RESEARCH · 04

Inflammatory markers as predictors.

Chronic low-grade inflammation, indexed by hs-CRP, IL-6, and homocysteine, is among the most reproducible early signals of cardiovascular and cognitive trajectory. The protocol panel reports these alongside lipids for that reason.

→ See citations

REFERENCES

Peer-reviewed, by area.

Hormones · Research 01

  1. 01Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018.
  2. 02Morgentaler A, et al. Fundamental concepts regarding testosterone deficiency and treatment. Mayo Clin Proc. 2016.
  3. 03Yeap BB, et al. Endogenous testosterone, dihydrotestosterone, and oestradiol levels and the risk of all-cause mortality in older men. Eur J Endocrinol. 2014.
  4. 04Travison TG, et al. Harmonized reference ranges for circulating testosterone levels in men of four cohort studies. J Clin Endocrinol Metab. 2017.
  5. 05Snyder PJ, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016.

NAD+ · Research 02

  1. 01Yoshino J, et al. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 2018.
  2. 02Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016.
  3. 03Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018.
  4. 04Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015.

Peptides · Research 03

  1. 01Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018.
  2. 02Sinha DK, et al. Beyond the androgen receptor: The role of growth hormone secretagogues in the modern management of body composition. Transl Androl Urol. 2020.
  3. 03Khorram O, et al. Effects of [norleucine27]growth hormone-releasing hormone on the immune system of aging men and women. J Clin Endocrinol Metab. 1997.
  4. 04Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006.

Inflammatory markers · Research 04

  1. 01Ridker PM, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997.
  2. 02Ridker PM, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000.
  3. 03Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018.
  4. 04Selhub J, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA. 1993.
  5. 05Holick MF. Vitamin D deficiency. N Engl J Med. 2007.

OUR PHYSICIANS

Reviewed and prescribed by licensed physicians.

Every protocol is reviewed and prescribed by a board-certified physician on the OpenLoop network, licensed in your state of residence. Physicians read your full intake, your baseline panel, and any flagged biomarkers before signing.

The review cadence is quarterly. Follow-up bloodwork is included; protocols are titrated to your numbers, not to a fixed schedule. If your bloodwork doesn’t support a protocol, we tell you that — and we don’t charge for the panel.

Board-certified50 statesQuarterly review

BUILT ON WHAT'S MEASURED

Built on what's measured.

A baseline panel. A licensed physician. A protocol you can read in plain English.

Start your assessment
The Science · Ody Health